GleamWall
中文EN

NXL Nexalin Technology, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1527352 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY76.7%
TTM net income YoY-8.0%
TTM EPS YoY108.1%
Revenue 3-yr CAGR29.2%
Net income 3-yr CAGR—

Margins

Gross margin82.4%
Operating margin-3,386.0%
Net margin-3,380.6%
FCF margin—
EBITDA margin—

Returns

ROE-372.6%
ROA-222.9%
ROIC (approx.)-406.6%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets92.0%
Debt / equity0.00x
Current ratio0.69x
Interest coverage-179.02x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-74.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$78,301$12,161$14,950$171,895$18,149$70,588$41,015$27,179
Cost of revenue$22,620$3,264$1,817$21,029$3,948$22,838$13,558$7,496
Gross profit$55,681$8,897$13,133$150,866$14,201$47,750$27,457$19,683
R&D expense$219,834$564,480$346,382$224,940$226,520$225,774$406,288$737,241
SG&A expense$1.43M$782,571$792,797$1.16M$1.42M$893,836$929,220$1.35M
Operating income-$2.61M-$2.25M-$2.12M-$2.41M-$2.35M-$1.62M-$2.01M-$2.88M
Interest expense$52,771-$129-$34-$159-$2,288-$4,690-$1,103-$1,823
Pretax income-$2.66M-$2.24M-$2.10M-$2.38M-$2.28M-$1.58M-$1.99M-$2.83M
Net income-$2.66M-$2.24M-$2.10M-$2.38M-$2.28M-$1.58M-$1.99M-$2.83M
EBITDA-$2.57M-$2.24M-$2.12M—-$2.34M———
EPS (basic)-3.43-0.11-0.11—-3.84-0.10-0.15—
EPS (diluted)-3.43-0.11-0.11—-3.84-0.10-0.15—
Weighted avg. shares (diluted)776,65721.14M19.82M—593,12815.72M13.31M—
Banking
Net interest income$52,771-$129-$34-$159-$2,288-$4,690-$1,103-$1,823
Balance sheet
Cash & equivalents$793,139$1.00M$1.21M$654,783$590,075$431,320$622,029$574,485
Short-term investments——$1.50M$3.07M$3.76M$5.36M$1.43M$2.91M
Receivables$118,285$52,930$43,004$81,571$7,925$59,841$14,479$13,043
Inventory$207,270$233,462$179,489$131,473$160,225$172,974$175,253$174,578
Current assets$1.89M$1.86M$3.29M$4.30M$4.82M$6.27M$2.62M$3.96M
PP&E, net$38,326$42,432——————
Intangibles—$399,501$359,310$336,049$308,562$294,871$279,520$260,727
Total assets$3.29M$3.00M$3.69M$4.64M$5.13M$6.56M$2.90M$4.22M
Current liabilities$2.76M$1.48M$808,364$887,333$357,524$600,584$574,736$546,694
Total liabilities$3.02M$1.48M$808,364$887,333$357,524$600,584$574,736$546,694
Shareholders' equity$263,342$1.52M$2.89M$3.75M$4.77M$5.96M$2.33M$3.68M
Shares outstanding828,93422.00M20.58M639,54418.19M17.42M13.33M13.30M
Cash flow statement
Operating cash flow-$1.59M-$1.80M-$1.71M-$1.15M-$1.47M-$917,165-$1.43M-$1.13M
Investing cash flow-$44,173$1.46M$1.51M$689,180$1.63M-$3.92M$1.47M$1.63M
Financing cash flow$1.42M$138,365$756,421$523,550$0——$0
Depreciation & amortization$36,866$2,738$4,106—$5,473———
Stock-based compensation$923,494$408,387$478,611$831,529$1.08M$572,100$636,844$1.55M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.